Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.74 |
| ▸ | CTSS | P25774 | 7/20 | 0.74 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10605035 | 1.00 | CTSK (0.74) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL10774431 | 0.92 | CTSK (0.72) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL19955305 | 0.92 | CTSK (0.72) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL4764611 | 0.87 | CTSK (0.75) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL4774352 | 0.87 | CTSK (0.75) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL25869316 | 0.87 | CTSK (0.58) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL30312609 | 0.86 | CTSS (0.56) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL13702232 | 0.86 | CTSS (0.56) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL27152033 | 0.86 | ITGB3 (0.59) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL27152032 | 0.86 | ITGB3 (0.59) | CTSKCTSSCTSLCTSBITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580852-B2 | 2-oxamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudopeptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120095096-A1 | 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010123832-A2 | 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095096-A1 | 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES | PLA2G2E, PLA2G4A, PLAA | CTSK 2760/4885CTSS 2394/4885CTSL 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.